CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis. The Italian generic drug and API maker said Tuesday that it is buying an API ...

Dublin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients Industry in India (2025 - 2030)" report has been added to ResearchAndMarkets.com's offering. In 2023, the active ...

India is the largest provider of generic drugs globally. Indian pharmaceutical industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 ...

The active pharmaceutical ingredients (API) industry in the country is at a watershed moment, impacted by global supply chain dynamics, shifting regulatory landscapes, and the desire for self-reliance ...

ANKLESHWAR, India--(BUSINESS WIRE)--RUSAN PHARMA PRIVATE LIMITED, a pharmaceutical company based in India specializing in the area of addiction treatment and pain management, recently announced that ...

Indian API industry players faced considerable volatility in earnings over FY2021-FY2023 on account of multiple headwinds such as rising raw material costs due to elevated crude oil prices and ...

Indian drugmaker Mankind Pharma intends to add an active pharmaceutical ingredient (API) manufacturing facility to its network of 16 production plants in India. The company says it will invest about ...

(MENAFN- GlobeNewsWire - Nasdaq) The Indian Active Pharmaceutical Ingredients (API) market, valued at INR 1.07 trillion in 2023, is set to reach INR 1.82 trillion by 2030, growing at a CAGR of ~8.26%.